|
|
| |
| Sero-detection of Epstein- Barr Virus among Patients with Nasopharyngeal Carcinoma Attending National Cancer Institute, University of Gezira - Sudan |
Alaa Abdallateef Abdalgader Alzain, Yousif Abdelhameed Mohammed, Adam Dawoud Abakar Salim, Elhadi Abdalla Ahmed, Albadawi Abdelbagi Talha
|
Abstract:
Background: Epstein-Barr virus (EBV) infects around 95% of the world’s population. This infection has been linked with lymphoid and epithelial cancers; persistence of infection in lymphoid or epithelial cells may result in virus-associated B-cell tumors or nasopharyngeal carcinomas (NPC). Objective: The study aimed to detect Epstein-Barr virus antibodies (IgG) against viral capsid antigen (VCA) among patients with nasopharyngeal carcinoma. Methodology: Descriptive laboratory, hospital based study was conducted in National Cancer Institute, University of Gezira, Sudan during March to October 2017. A total of 61 patients with NPC were included; structured questionnaire was designed to collect the data. Blood samples were collected into lithium heparin anticoagulant and plasma was tested for EBV antibodies (IgG) against VCA by quantitative enzyme linked immune sorbent assay (ELISA). Results: From a total of 61 cases there were 62.3% (38/61) males and 37.7% (23/61) females with ratio 2:1 (Male:Female), the age ranged between 4 to 70 years, with their means of (39.7 ± 17.2). Squamous cell carcinoma was the most common histopathological subtype and accounted of 91.8% (56/61). Most of NPC patients were within WHO typing; type III was 90.2% followed by type II. VCA antibodies (IgG) of EBV was detected with 93.4% (57/61) of studies cases. There was no significant differences between age, sex, WHO typing and NPC stage. However there was a significant correlation (P=0.05) between histopathology and the present of EBV. Conclusion: VCA antibodies (IgG) of EBV was significantly detected among patients with nasopharyngeal carcinoma especially, squamous cell carcinoma and WHO type III.
|
|
|
| | |